Trial Profile
A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Sep 2019 Status changed from recruiting to discontinued.
- 09 Aug 2011 New trial record